激智科技(300566.SZ):葉伍元及俞根偉減持期屆滿 合計減持285.81萬股
格隆匯12月31日丨激智科技(300566.SZ)公佈,2019年12月31日,公司收到葉伍元和俞根偉分別出具的《關於股份減持計劃期限屆滿的告知函》。俞根偉於2019年9月17日至11月5日期間,通過集中競價方式減持公司股份共131.63萬股;葉伍元於2019年9月19日至12月19日期間,通過集中競價方式減持公司股份共154.18萬股。截止公告披露日,葉伍元和俞根偉減持計劃期限已屆滿,合計減持285.81萬股。
此次減持後,俞根偉持有股份1118.16萬股,佔公司總股本比例7.20%;葉伍元持有股份1033.61萬股,佔公司總股本比例6.66%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.